German evaluation of niraparib in Clinical Practice – An evaluation of clinical experience during the Compassionate Use Program (CUP) in Germany

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016716

Enrollment

100

Registered

2019-03-07

Start date

2019-09-17

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer, fallopian tube cancer, or primary peritoneal cancer C56 C57.0 C78.6

Interventions

Group 1: Retrospective information on the patients' previous medical history, tumor characteristics and concomitant diseases is collected from all participating patients and entered into the eCRF. In

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients have initiated niraparib treatment during the CUP in Germany

Exclusion criteria

Exclusion criteria: Lack of signed informed consent

Design outcomes

Primary

Measure	Time frame
Safety, compatibility and adherence in handling Niraparib. Are there risk factors for the occurrence of side effects? What is the average dosage after dose adjustment became necessary? How long does treatment with niraparib take?	—

Secondary

Measure	Time frame
Improvement of the practicle use of Niraparib as maintainance therapie.	—

Countries

Germany

Contacts

Public ContactJolijn Boer

NOGGO e.V.

jolijn.boer@noggo.de004930403686534

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026